Skip to main content

Table 3 Univariate and multivariate analysis on factors associated with WHR increase > 10% from diagnosis to T3 assessment, by stepwise logistic regression (n = 1171)

From: Weight and waist-to-hip ratio change pattern during the first five years of survival: data from a longitudinal observational Chinese breast cancer cohort

 

Univariate analysis

Multivariate analysis

OR

95%CI for OR

P

OR

95%CI for OR

P

Age group at diagnosis, year

  

0.031

  

0.033

 < 40

1

–

–

1

–

–

 40–49

0.572

0.352–0.927

0.024

0.587

0.361–0.956

0.032

 50–59

0.774

0.486–1.233

0.281

0.923

0.571–1.493

0.946

 ≥60

0.520

0.305–0.886

0.016

0.684

0.390–1.200

0.237

Education level

  

0.200

   

High school or below

1

–

    

College or above

1.272

0.881–1.836

    

Marital status

      

Married or cohabitation

1

–

    

Unmarried or divorced or widowed

1.105

0.814–1.501

0.522

   

Family income, HKD/month

 < 30,000

1

–

    

 ≥30,000

1.184

0.855–1.638

0.310

   

Employment status

      

 Working

1

–

    

 Not working

1.228

0.928–1.625

0.150

   

Number of comorbidities

  

0.006

  

0.009

 0

1

–

 

1

–

 

 1

0.878

0.633–1.217

0.434

0.859

0.610–1.210

0.385

 ≥2

0.418

0.245–0.713

0.001

0.417

0.238–0.732

0.002

Menopausal status from T0 to

  

0.445

   

T3 assessment

      

 Pre-menopausal

1

–

    

 Peri-menopausal

1.146

0.760–1.727

0.515

   

Post-menopausal

0.941

0.629–1.409

0.768

   

Parity

  

0.259

   

 0

1

–

    

 ≥1

0.832

0.605–1.145

    

AJCC stage

  

0.203

   

 0-I

1

–

    

 II

0.840

0.620–1.136

0.258

   

 III

0.691

0.452–1.057

0.089

   

ER status, %

 Positive

1

  

1

  

 Negative

0.663

0.471–0.933

0.019

0.624

0.440–0.886

0.008

PR status, %

 Positive

1

     

 Negative

0.895

0.674–1.189

0.444

   

HER 2 status, %

 Positive

1

     

 Negative

1.124

0.814–1.554

0.478

   

Type of surgery

 Mastectomy

1

–

    

Conservation

1.236

0.931–1.640

0.143

   

Chemotherapy, %

 No

1

–

    

 Yes

0.780

0.571–1.065

0.118

   

Radiotherapy, %

 No

1

     

 Yes

1.081

0.794–1.472

0.621

   

Endocrine therapy, %

 No

1

–

    

 Yes

1.229

0.882–1.712

0.223

   

Average sports participation

  

0.655

   

from T1 to T3 assessment

      

Never

1

–

    

Rarely/occasionally

0.843

0.543–1.311

0.449

   

 Frequently

0.942

0.595–1.491

0.799

   

Average dietary energy intake from T1 to T3 assessment

 ≤median

1

–

    

 >median

1.010

0.764–1.336

0.943

   

Average dietary carbohydrate intake from T1 to T3

 assessment, g/1000 kcal/day

      

 ≤median

1

–

    

 >median

1.052

0.796–1.391

0.722

   

Average dietary fat intake from T1 to T3 assessment, g/1000

 kcal/day

      

 ≤median

1

–

    

 >median

1.096

0.829–1.449

0.522

   

Average vegetables and fruits intake from T1 to T3 assessment, g/day

 < 400

1

–

    

 ≥400

0.792

0.550–1.140

0.210

   

Average coffee intake from T1 to T3 assessment, ml/week

 < 200

1

–

    

 ≥200

0.914

0.662–1.261

0.584

   

Average sugar-sweetened beverage intake from T1 to T3

 assessment, ml/week

      

 < 200

1

–

    

 ≥200

0.802

0.489–1.316

0.383

   
  1. Univariate logistic regression was performed to identify any potential factors associated with very substantial weight gain from diagnosis to T3 assessment. The potential variables with P < 0.1 in univariate analysis were included into the multivariate logistic regression model, including age group at diagnosis, number of comorbidities and ER status
  2. From T0 to T3 assessment, patients’ menopause status could be classified as three groups: pre-menopausal, peri-menopausal and post-menopausal. Peri-menopausal was defined as pre-menopausal patients at T0 who described a change in menopause status at T3
  3. Abbreviations: WHR waist-to-hip ratio; OR odds ratio; CI confidence interval; HKD Hong Kong dollars; AJCC American joint Committee on cancer; ER estrogen receptor; PR progesterone receptor; HER 2 human epidermal-growth-factor receptor 2; MET metabolic equivalent of task; g gram
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us